Table 2.
Characteristics of patients with inflammatory bowel diseases in this study.
| Patients | Gender | Age (years) | Disease duration (years) | Location of the lesion | Procedure | Medication |
|---|---|---|---|---|---|---|
| BD1 | F | 37 | 2 | IL | Resection | PSL 50 mg/day, AZP 100 mg/day |
| BD2 | M | 31 | 5 | CO | Biopsy | None |
| BD3 | M | 55 | 22 | CO | Biopsy | PSL 10 mg/day, SASP 3000 mg/day |
| BD4 | F | 40 | 1 | CO | Biopsy | PSL 30 mg/day |
| CD1 | F | 32 | 5 | IL/CO | Biopsy | Naproxen 300 mg/day |
| CD2 | M | 26 | 7 | CO | Biopsy | AZP50mg/day, mesalazine 3000 mg/day |
| CD3 | M | 32 | 1 | IL/CO | Biopsy | Mesalazine 3000 mg/day |
| CD4 | M | 29 | 1 | IL/CO | Biopsy | Mesalazine 1500 mg/day |
BD, Behçet's disease; IL, ileum; CO, colon; PSL, prednisone; AZP, azathioprine; SASP, salazosulphapyridine.